探索加拿大医护人员和免疫专家对现有肺炎球菌结合疫苗的接受度
研究访谈了21名加拿大免疫委员会成员及一线医护人员,多数受访者偏好PCV-13而非PCV10,认为急性中耳炎不应作为接种计划决策的考量因素,且PCV10对19A交叉保护的新证据未改变偏好但影响了对定价的看法。
要点
- 多数受访者偏好PCV-13而非PCV10。
- 急性中耳炎被视为重要结局,但因缺乏监测而不宜作为项目成功指标。
- PCV10对19A交叉保护的新证据未改变偏好,但影响了对定价的看法。
核心结论
- 多数受访者偏好PCV-13而非PCV10,认为急性中耳炎不应作为肺炎球菌疫苗接种计划决策的考量因素。
- 若要考虑对现行计划做出任何改变,多数受访者需要更多关于PCV10交叉保护和对中耳炎有效性的证据。
- 降低疫苗价格被提及为同时资助两种疫苗的积极结果。
研究设计与样本
- 访谈了21名加拿大免疫委员会成员和/或一线医护人员。
主要发现
- 多数受访者偏好PCV-13而非PCV10。
- 对多数受访者而言,急性中耳炎不应被纳入肺炎球菌疫苗接种计划实施的决策考量。
- 急性中耳炎被视为项目的重要结局,但因缺乏对该病的监测而被认为不是衡量项目成功的有效指标。
- 关于PCV10对19A交叉保护的最新证据未影响偏好,但影响了对定价的看法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In children, the 13 and 10-valent pneumoccocal conjugate vaccines (PCV13/10) are currently approved for the prevention of invasive pneumococcal disease (IPD). Acceptability is a key consideration in the implementation of a vaccine program and it is recognized that health professional's attitudes and opinions towards vaccines are independent predictors of the success of an immunization program. We aimed to survey the beliefs and attitudes for the two available PCVs in health care professionals and immunization experts. FINDINGS: We interviewed 21 members of Canadian immunization committees and/or participants working in frontline healthcare delivery. Overall, participants predominantly preferred PCV-13 over PCV10. For most, AOM should not be taken into considerations in decisions for pneumococcal vaccination programs implementation. AOM was considered an important endpoint of the program but an ineffective measure of program success due to the lack of surveillance for the condition. Recent evidence pertaining to PCV10 cross-protection against 19A did not affect preference but had an impact on perceptions regarding pricing. CONCLUSION: To consider implementing any changes to the current program, most participants would require more evidence regarding PCV10 cross-protection and effectiveness against OM. Decreasing vaccine price was cited as a positive outcome of funding both vaccines.
引用
- Berman M, Dubé E, Quach C, et al. Exploring the acceptability of the available pneumococcal conjugate vaccines in Canadian health care professionals and immunization experts. Vaccine. 2017. PMID: 28501455. doi:10.1016/j.vaccine.2017.04.083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。